Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study)

Sleep Medicine

Volumn 9, Issue 5, 2008, Pages 537-541

  Partinen, Markku ^a,e   Hirvonen, Kari ^a,b   Jama, Leni ^a,e   Alakuijala, Anniina ^a,c   Hublin, Christer ^d,e   Tamminen, Ilkka ^f   Koester, Juergen ^g   Reess, Juergen ^g  

^a Rinnekoti Foundation Finland   (Finland)

^b Neurotest Tampere Oy   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f Boehringer Ingelheim Finland Ky   (Finland)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

CGI I; ESS; Long term efficacy; PGI I; Pramipexole; Restless Legs Syndrome; RLS; SF 36

Indexed keywords

PRAMIPEXOLE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPWORTH SLEEPINESS SCALE; FATIGUE; FEMALE; FINLAND; HUMAN; INFLUENZA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RATING SCALE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SHORT FORM 36; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; BENZOTHIAZOLES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PATIENT SATISFACTION; RESTLESS LEGS SYNDROME; SLEEP; TREATMENT OUTCOME; YOUNG ADULT;

EID: 44449160208     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2007.12.004     Document Type: Article

References (15)

1. Earley C.J. Clinical practice. Restless legs syndrome. N Engl J Med 348 (2003) 2103-2109
2. Allen R.P., et al., for the Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health. Sleep Med 4 (2003) 101-119
3. Allen R.P., and Earley C.J. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 18 (2001) 128-147
4. Allen R.P., Walters A.S., Montplaisir J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165 (2005) 1286-1292
5. Hening W., Walters A.S., Allen R.P., Montplaisir J., Myers A., and Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 5 (2004) 237-246
6. Abetz L., Vallow S.M., Kirsch J., Allen R.P., Washburn T., and Earley C.J. Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health 8 (2005) 157-167
7. Trenkwalder C., Paulus W., and Walters A.S. The restless legs syndrome. Lancet Neurol 4 (2005) 465-475
8. Partinen M., Hirvonen K., Jama L., et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study - the PRELUDE study. Sleep Med 7 (2006) 407-417
9. Trenkwalder C., Stiasny-Kolster K., Kupsch A., Oertel W.H., Koester J., and Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 21 (2006) 1404-1410
10. Winkelman J.W., Sethi K.D., Kushida C.A., et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 67 (2006) 1034-1039
11. Walters A.S., et al., for the International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4 (2003) 121-132
12. National Institute of Mental Health (NIMH). Early clinical drug evaluation unit (ECDEU). Clinical Global Impressions. In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rev. ed. Rockville, Md, NIMH USA; 1976. p. 216-22.
13. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14 (1991) 540-545
14. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
15. Trenkwalder C., et al., for the Therapy with Ropinirole; Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75 (2004) 92-97